In the fall of 2020, public health officials reported that multiple variants of the SARS-CoV-2 virus had emerged and were circulating worldwide. Like all viruses, SARS-CoV-2 continually evolve because genetic mutations happen during the genome’s replication. A variant is the result of one or more genetic mutations.
In the United Kingdom, the B.1.1.7 variant (Alpha) emerged in September 2020, and by January 22, 2021 it was confirmed as the dominant circulating strain in England. The transmissibility of this variant was reportedly greater than other circulating SARS-CoV-2 virus variants. Health officials reported that this variant appeared to be 30 to 80 percent more transmissible and increased a person’s risk of death by 30 percent.
The B.1.351 variant (Beta) was initially detected in Nelson Mandela Bay in South Africa in early October 2020. By December 2020, this variant was found to be the predominant variant circulating in Zambia.
The P.1.(Gamma) variant was first detected in Japan in four travelers from Brazil. In late December, 42 percent of positive samples collected in Manaus, the largest city in the Amazon region of Brazil, were the P.1. variant. Public health officials expressed concerns that this variant could be transmitted more effectively or be responsible for re-infection.
On February 11, 2021, the Journal of the American Medical Association (JAMA) published a letter from researchers reporting on a novel SARS-CoV-2 variant, the CAL.20C variant (now B.1.427/B.1.429 or Epsilon), that had emerged in late 2020 in Southern California. By mid-January 2021, this variant was found to account for 35 percent of SARS-CoV-2 specimens from California, and 44 percent of specimens from Southern California.
Another variant, the B.1.526 (Iota) variant, was identified by research teams from Columbia University and the California Institute of Technology (CalTech). Both teams of researchers found that the strain was detected in New York in November 2020 and that the variant may represent an antigenic drift in the virus with possible blunting of current vaccine effectiveness.
On May 4, 2021, the CDC classified the SARS-CoV-2 variant B.1.617 (Delta) as a variant of interest. This variant, which originated in India, was declared a variant of concern by the World Health Organization (WHO) on May 10, 2021. According to the WHO, the Delta variant was associated with increased transmissibility and decreased neutralization. As a result, vaccinated individuals and persons who have previously recovered from a COVID-19 infection could be at risk for infection from this variant.
By the end of June 2021, almost 90 percent of COVID-19 cases in Israel were reported as being from the Delta variant, with 50 percent occurring in fully vaccinated adults. Health experts reported the Delta variant to be more easily transmissible and that vaccinated individuals were capable of spreading the virus on to others, as COVID-19 vaccines were unable to stop viral transmission.
The C.37 variant (Lambda), first identified in Peru in August 2020, was classified by WHO as a Variant of Interest on June 14, 2021. The Lambda variant was reported to be highly contagious and more resistant to vaccines.
On August 30, 2021, WHO designated the Mu variant a Variant of Interest. Initially identified in Columbia in January 2021, this variant, also known as B.1.621, became increasingly prevalent in South America. WHO reported that "the Mu variant has a constellation of mutations that indicate potential properties of immune escape," but stated that further studies were needed on the variant.
Resurgence of Cases related to the Omicron Variant
The B.1.1.529 variant (Omicron), which was initially identified in early November 2021 in South Africa, was labeled a Variant of Concern by WHO on November 26, 2021. According to WHO, the variant was concerning because it contained a significant number of mutations. Many countries, including the U.S., announced that travel restrictions from eight African countries would be implemented by the end of November 2021 in an attempt to curb spread of the new variant. Top South African health officials reported that while the variant appeared to be highly transmissible, symptoms were “extremely mild”.
In late November 2021, health officials declared the Omicron variant a Variant of Concern. By December of 2021, health officials reported that cases associated with the variant would surge to record numbers and likely peak in mid-January 2022. The variant, however, has been associated with lower rates of hospitalization, shorter in-patient stays, and lower fatality rates.
As of August 27, 2023, the Omicron variant continues to be labeled a Variant of Concern by the CDC.
IMPORTANT NOTE: NVIC encourages you to become fully informed about COVID-19 and the COVID-19 vaccine by reading all sections in the table of contents, which contains many links and resources such as the manufacturer product information inserts, and to speak with one or more trusted health care professionals before making a vaccination decision for yourself or your child. This information is for educational purposes only and is not intended as medical advice.